D
Crinetics Pharmaceuticals, Inc.
CRNX
$34.47
-$0.57-1.63%
D
Sell
3/14/2023Downgrade
Crinetics Pharmaceuticals, Inc. (CRNX) was downgraded to D- from D on 3/14/2023 due to a decline in the growth index and solvency index. The quick ratio declined from 15.09 to 12.15, EBIT declined 9.44% from -$43.45M to -$47.56M, and earnings per share declined from -$0.7797 to -$0.8357.
Crinetics Pharmaceuticals, Inc. (CRNX) was downgraded to D- from D on 3/14/2023 due to a decline in the growth index and solvency index. The quick ratio declined from 15.09 to 12.15, EBIT declined 9.44% from -$43.45M to -$47.56M, and earnings per share declined from -$0.7797 to -$0.8357.
D
Sell
2/23/2023Upgraded
Crinetics Pharmaceuticals, Inc. (CRNX) was upgraded to D from D- on 02/23/2023.
Crinetics Pharmaceuticals, Inc. (CRNX) was upgraded to D from D- on 02/23/2023.
D
Sell
2/8/2023Downgrade
Crinetics Pharmaceuticals, Inc. (CRNX) was downgraded to D- from D on 2/8/2023 due to a decline in the total return index, growth index and solvency index. Operating cash flow declined 37.54% from -$27.98M to -$38.48M, the quick ratio declined from 15.71 to 15.09, and EBIT declined 0.95% from -$43.05M to -$43.45M.
Crinetics Pharmaceuticals, Inc. (CRNX) was downgraded to D- from D on 2/8/2023 due to a decline in the total return index, growth index and solvency index. Operating cash flow declined 37.54% from -$27.98M to -$38.48M, the quick ratio declined from 15.71 to 15.09, and EBIT declined 0.95% from -$43.05M to -$43.45M.
D
Sell
6/7/2022Downgrade
Crinetics Pharmaceuticals, Inc. (CRNX) was downgraded to D from D+ on 6/7/2022 due to a decline in the volatility index.
Crinetics Pharmaceuticals, Inc. (CRNX) was downgraded to D from D+ on 6/7/2022 due to a decline in the volatility index.
D
Sell
5/23/2022Upgraded
Crinetics Pharmaceuticals, Inc. (CRNX) was upgraded to D+ from D on 5/23/2022 due to an increase in the growth index, volatility index and total return index. Total revenue increased 190.45% from $1.08M to $3.13M, and operating cash flow increased 40.86% from -$22.9M to -$13.54M.
Crinetics Pharmaceuticals, Inc. (CRNX) was upgraded to D+ from D on 5/23/2022 due to an increase in the growth index, volatility index and total return index. Total revenue increased 190.45% from $1.08M to $3.13M, and operating cash flow increased 40.86% from -$22.9M to -$13.54M.
D
Sell
5/5/2022Upgraded
Crinetics Pharmaceuticals, Inc. (CRNX) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
Crinetics Pharmaceuticals, Inc. (CRNX) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
D
Sell
4/20/2022Downgrade
Crinetics Pharmaceuticals, Inc. (CRNX) was downgraded to D- from D on 4/20/2022 due to a noticeable decline in the total return index and volatility index.
Crinetics Pharmaceuticals, Inc. (CRNX) was downgraded to D- from D on 4/20/2022 due to a noticeable decline in the total return index and volatility index.
D
Sell
11/9/2021Upgraded
Crinetics Pharmaceuticals, Inc. (CRNX) was upgraded to D from D- on 11/9/2021 due to an increase in the growth index and total return index.
Crinetics Pharmaceuticals, Inc. (CRNX) was upgraded to D from D- on 11/9/2021 due to an increase in the growth index and total return index.
D
Sell
11/8/2021Downgrade
Crinetics Pharmaceuticals, Inc. (CRNX) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index and growth index. EBIT declined 13.84% from -$22.92M to -$26.09M, and earnings per share declined from -$0.6937 to -$0.7041.
Crinetics Pharmaceuticals, Inc. (CRNX) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index and growth index. EBIT declined 13.84% from -$22.92M to -$26.09M, and earnings per share declined from -$0.6937 to -$0.7041.
D
Sell
4/1/2021Upgraded
Crinetics Pharmaceuticals, Inc. (CRNX) was upgraded to D from D- on 4/1/2021 due to an increase in the total return index and volatility index.
Crinetics Pharmaceuticals, Inc. (CRNX) was upgraded to D from D- on 4/1/2021 due to an increase in the total return index and volatility index.
D
Sell
8/7/2020Downgrade
Crinetics Pharmaceuticals, Inc. (CRNX) was downgraded to D- from D on 8/7/2020 due to a noticeable decline in the growth index and volatility index. Operating cash flow declined 29.64% from -$12.23M to -$15.86M.
Crinetics Pharmaceuticals, Inc. (CRNX) was downgraded to D- from D on 8/7/2020 due to a noticeable decline in the growth index and volatility index. Operating cash flow declined 29.64% from -$12.23M to -$15.86M.
D
Sell
5/26/2020Upgraded
Crinetics Pharmaceuticals, Inc. (CRNX) was upgraded to D from D- on 5/26/2020 due to a noticeable increase in the growth index.
Crinetics Pharmaceuticals, Inc. (CRNX) was upgraded to D from D- on 5/26/2020 due to a noticeable increase in the growth index.
D
Sell
5/8/2020Downgrade
Crinetics Pharmaceuticals, Inc. (CRNX) was downgraded to D- from D on 5/8/2020 due to a decline in the efficiency index, total return index and volatility index. Net income declined 19.32% from -$14.55M to -$17.36M, and total capital declined 7.23% from $122.71M to $113.84M.
Crinetics Pharmaceuticals, Inc. (CRNX) was downgraded to D- from D on 5/8/2020 due to a decline in the efficiency index, total return index and volatility index. Net income declined 19.32% from -$14.55M to -$17.36M, and total capital declined 7.23% from $122.71M to $113.84M.
D
Sell
1/24/2020Upgraded
Crinetics Pharmaceuticals, Inc. (CRNX) was upgraded to D from D- on 1/24/2020 due to an increase in the growth index, volatility index and total return index.
Crinetics Pharmaceuticals, Inc. (CRNX) was upgraded to D from D- on 1/24/2020 due to an increase in the growth index, volatility index and total return index.
D
Sell
8/14/2019Downgrade
Crinetics Pharmaceuticals, Inc. (CRNX) was downgraded to D- from D on 8/14/2019 due to a noticeable decline in the growth index, total return index and efficiency index. Operating cash flow declined 85.94% from -$6.76M to -$12.57M, net income declined 37.83% from -$9.02M to -$12.43M, and earnings per share declined from -$0.3742 to -$0.5143.
Crinetics Pharmaceuticals, Inc. (CRNX) was downgraded to D- from D on 8/14/2019 due to a noticeable decline in the growth index, total return index and efficiency index. Operating cash flow declined 85.94% from -$6.76M to -$12.57M, net income declined 37.83% from -$9.02M to -$12.43M, and earnings per share declined from -$0.3742 to -$0.5143.
D
Sell
8/1/2019Upgraded
Crinetics Pharmaceuticals, Inc. (CRNX) was upgraded to D from D- on 8/1/2019 due to an increase in the efficiency index.
Crinetics Pharmaceuticals, Inc. (CRNX) was upgraded to D from D- on 8/1/2019 due to an increase in the efficiency index.
D
Sell
4/1/2019Upgraded
Crinetics Pharmaceuticals, Inc. (CRNX) was upgraded to D- from E on 4/1/2019 due to an increase in the growth index. Total revenue increased 42.52% from $548 to $781, and earnings per share increased from -$0.3791 to -$0.3533.
Crinetics Pharmaceuticals, Inc. (CRNX) was upgraded to D- from E on 4/1/2019 due to an increase in the growth index. Total revenue increased 42.52% from $548 to $781, and earnings per share increased from -$0.3791 to -$0.3533.
E
Sell
2/21/2019Downgrade
Crinetics Pharmaceuticals, Inc. (CRNX) was downgraded to E from E+ on 2/21/2019 due to a noticeable decline in the volatility index.
Crinetics Pharmaceuticals, Inc. (CRNX) was downgraded to E from E+ on 2/21/2019 due to a noticeable decline in the volatility index.
E
Sell
2/4/2019Upgraded
Crinetics Pharmaceuticals, Inc. (CRNX) was upgraded to E+ from E on 2/4/2019 due to a large increase in the volatility index and total return index.
Crinetics Pharmaceuticals, Inc. (CRNX) was upgraded to E+ from E on 2/4/2019 due to a large increase in the volatility index and total return index.
E
Sell
1/18/2019Downgrade
Crinetics Pharmaceuticals, Inc. (CRNX) was downgraded to E from E+ on 1/18/2019 due to a large decline in the volatility index and total return index.
Crinetics Pharmaceuticals, Inc. (CRNX) was downgraded to E from E+ on 1/18/2019 due to a large decline in the volatility index and total return index.
E
Sell
1/3/2019Upgraded
Crinetics Pharmaceuticals, Inc. (CRNX) was upgraded to E+ from E on 1/3/2019 due to a significant increase in the solvency index, total return index and volatility index. The quick ratio increased from 12.35 to 30.86.
Crinetics Pharmaceuticals, Inc. (CRNX) was upgraded to E+ from E on 1/3/2019 due to a significant increase in the solvency index, total return index and volatility index. The quick ratio increased from 12.35 to 30.86.
E
Sell
10/10/2018None
Crinetics Pharmaceuticals, Inc. (CRNX) was downgraded to E from U on 10/10/2018.
Crinetics Pharmaceuticals, Inc. (CRNX) was downgraded to E from U on 10/10/2018.
NASDAQ
03/14/2025 4:00PM Eastern
Quotes delayed
